Literature DB >> 11050183

A targeted mutation in the IL-4Ralpha gene protects mice against autoimmune diabetes.

D L Radu1, N Noben-Trauth, J Hu-Li, W E Paul, C A Bona.   

Abstract

Autoimmune insulin-dependent diabetes mellitus (IDDM) occurs spontaneously in mice-bearing transgenes encoding the influenza hemagglutinin under the control of the rat insulin promoter and a T cell receptor specific for an hemagglutinin peptide associated with I-E(d). Such "double transgenic" mice expressing wild-type or targeted IL-4Ralpha genes were examined for the onset of IDDM. Eight of 11 mice homozygous for wild-type IL-4Ralpha were hyperglycemic by 8 weeks of age, whereas only 1 of 16 mice homozygous for the targeted allele were hyperglycemic at this time. Most 1L-4Ralpha-/- mice remained normoglycemic to 36 weeks of age. Although only 10% of double transgenic mice homozygous for the wild-type IL-4Ralpha allele survived to 30 weeks, 80% of mice homozygous for the targeted allele did so. Heterozygous mice displayed an intermediate frequency of diabetes. Even as late as 270 days of age, mice homozygous for the targeted allele had no insulitis or only peri-insulitis. Thus, the inability to respond to IL-4 and/or IL-13 protects mice against IDDM in this model of autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11050183      PMCID: PMC18827          DOI: 10.1073/pnas.230431397

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Autoimmune insulitis and diabetes in the absence of antigen-specific contact between T cells and islet beta-cells.

Authors:  A Sarukhan; O Lechner; H von Boehmer
Journal:  Eur J Immunol       Date:  1999-10       Impact factor: 5.532

2.  The temporal importance of TNFalpha expression in the development of diabetes.

Authors:  E A Green; R A Flavell
Journal:  Immunity       Date:  2000-05       Impact factor: 31.745

3.  Different role of IL-4 in the onset of hapten-induced contact hypersensitivity in BALB/c and C57BL/6 mice.

Authors:  H Nagai; Y Ueda; T Ochi; Y Hirano; H Tanaka; N Inagaki; K Kawada
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

4.  Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response.

Authors:  M B Oldstone; M Nerenberg; P Southern; J Price; H Lewicki
Journal:  Cell       Date:  1991-04-19       Impact factor: 41.582

5.  Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma.

Authors:  M Debray-Sachs; C Carnaud; C Boitard; H Cohen; I Gresser; P Bedossa; J F Bach
Journal:  J Autoimmun       Date:  1991-04       Impact factor: 7.094

6.  Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice.

Authors:  P S Ohashi; S Oehen; K Buerki; H Pircher; C T Ohashi; B Odermatt; B Malissen; R M Zinkernagel; H Hengartner
Journal:  Cell       Date:  1991-04-19       Impact factor: 41.582

7.  Disruption of the murine IL-4 gene blocks Th2 cytokine responses.

Authors:  M Kopf; G Le Gros; M Bachmann; M C Lamers; H Bluethmann; G Köhler
Journal:  Nature       Date:  1993-03-18       Impact factor: 49.962

8.  Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice.

Authors:  I L Campbell; T W Kay; L Oxbrow; L C Harrison
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

9.  Sensitization to self (virus) antigen by in situ expression of murine interferon-gamma.

Authors:  M S Lee; M von Herrath; H Reiser; M B Oldstone; N Sarvetnick
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

10.  Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice.

Authors:  M J Rapoport; A Jaramillo; D Zipris; A H Lazarus; D V Serreze; E H Leiter; P Cyopick; J S Danska; T L Delovitch
Journal:  J Exp Med       Date:  1993-07-01       Impact factor: 14.307

View more
  7 in total

1.  The protein tyrosine phosphatase SHP-1 modulates the suppressive activity of regulatory T cells.

Authors:  Tessy Iype; Mohan Sankarshanan; Ileana S Mauldin; David W Mullins; Ulrike Lorenz
Journal:  J Immunol       Date:  2010-10-15       Impact factor: 5.422

Review 2.  Role of cytokines as mediators and regulators of microglial activity in inflammatory demyelination of the CNS.

Authors:  Tobias D Merson; Michele D Binder; Trevor J Kilpatrick
Journal:  Neuromolecular Med       Date:  2010-03-30       Impact factor: 3.843

3.  Differential regulation of IL-4Ralpha expression by antigen versus cytokine stimulation characterizes Th2 progression in vivo.

Authors:  Georgia Perona-Wright; Katja Mohrs; Katrin D Mayer; Markus Mohrs
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

4.  Amelioration of experimental autoimmune encephalomyelitis in IL-4Ralpha-/- mice implicates compensatory up-regulation of Th2-type cytokines.

Authors:  Stefanie Gaupp; Barbara Cannella; Cedric S Raine
Journal:  Am J Pathol       Date:  2008-06-05       Impact factor: 4.307

5.  TRPV1 properties in thoracic dorsal root ganglia neurons are modulated by intraperitoneal capsaicin administration in the late phase of type-1 autoimmune diabetes.

Authors:  Beatrice Mihaela Radu; Adina Daniela Iancu; Diana Ionela Dumitrescu; Maria Luisa Flonta; Mihai Radu
Journal:  Cell Mol Neurobiol       Date:  2012-10-31       Impact factor: 5.046

6.  TSH receptor-adenovirus-induced Graves' hyperthyroidism is attenuated in both interferon-gamma and interleukin-4 knockout mice; implications for the Th1/Th2 paradigm.

Authors:  Y Nagayama; O Saitoh; S M McLachlan; B Rapoport; H Kano; Y Kumazawa
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

7.  Deletion of IL-4 receptor alpha on dendritic cells renders BALB/c mice hypersusceptible to Leishmania major infection.

Authors:  Ramona Hurdayal; Natalie E Nieuwenhuizen; Mélanie Revaz-Breton; Liezel Smith; Jennifer C Hoving; Suraj P Parihar; Boris Reizis; Frank Brombacher
Journal:  PLoS Pathog       Date:  2013-10-24       Impact factor: 6.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.